> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tango Therapeutics Swings To $68.4 Million Loss As Cancer Development Costs Climb
- URL: https://www.bullished.co/tango-therapeutics-swings-to-68-4-million-loss-as-cancer-development-costs-climb-539321a5/
- Published: 2026-11-09T12:21:27.000Z
- Updated: 2026-11-09T12:21:27.000Z
- Description: Collaboration revenue fell to zero, while Tango prepares a late-stage pancreatic-cancer study and January data releases.
- Author: Matteo Parrino
- Tags: Earnings, TNGX, Industry: Healthcare

[Tango Therapeutics](https://www.bullished.co/tag/tngx/), which develops targeted cancer medicines, swung to a $68.4 million third-quarter loss from a $15.9 million profit a year earlier as collaboration revenue vanished and development and personnel costs rose. The company reported the results Monday in an earnings release accompanying its [SEC filing](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526452635/tngx-20260811.htm?ref=bullished.co).

## Gilead Revenue Ends, Spending Rises

Collaboration revenue was zero for both the third quarter and the first nine months, against $53.8 million and $62.4 million, respectively, a year earlier. Research under Tango’s Gilead collaboration ended in August 2025; the company recognized the remaining upfront and research option-extension payments as revenue that year.

Third-quarter research spending reached $48.9 million, against $30.8 million a year earlier. Tango attributed the increase mainly to advancing vopimetostat and TNG456, partly offset by cuts from portfolio prioritization. Nine-month research spending was $119.7 million, compared with $100.1 million.

Administrative expenses climbed to $29.2 million from $8.9 million in the quarter, largely because of personnel costs, including stock compensation and changes to former executives’ equity awards. For the first nine months, those expenses reached $67.0 million, against $31.7 million.

The quarterly loss amounted to $0.39 per share, compared with year-earlier earnings of $0.14 per basic share and $0.13 per diluted share. The nine-month loss widened to $169.2 million, or $1.08 per share, from $62.8 million, or $0.57 per share. Tango held [$977.5 million](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526452635/tngx-ex99%5F1.htm?ref=bullished.co) in cash, cash equivalents and marketable securities at September 30, which it expects to cover its current operating plan.

## Pancreatic Data Drive Trial Plans

Tango narrowed its research priorities in October to therapies targeting PRMT5\. Its approach exploits genetic vulnerabilities in tumors, aiming to kill cancer cells while sparing healthy tissue; vopimetostat targets non-brain cancers, while TNG456 is designed to reach the brain.

At the 2026 ESMO Congress in October, Tango reported an [82% response rate](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526452635/tngx-ex99%5F1.htm?ref=bullished.co) for vopimetostat combined with Revolution Medicines’ daraxonrasib in evaluable patients receiving second- or third-line treatment for pancreatic cancer with MTAP deletion and RAS mutations. The nine-month rate of survival without disease progression was 88%, and median progression-free survival had not been reached.

The efficacy analysis covered patients whose treatment began at least 14 weeks before the August 20, 2026 data cutoff. Tango said the combination was generally well tolerated at daily doses of 200 mg vopimetostat and 100 mg daraxonrasib.

Tango plans a global, randomized late-stage study in the first half of 2027 comparing that combination with chemotherapy in previously untreated MTAP-deleted pancreatic cancer. Its main goals will measure tumor response and survival without progression, with overall survival a key secondary measure.

Malte Peters, Tango’s president and chief executive officer, said, “we plan to engage with regulators on the possibility of seeking [accelerated approval](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526452635/tngx-ex99%5F1.htm?ref=bullished.co) of this combination in second line pancreatic cancer.”

## Erasca Enrollment And January Readouts

Tango and Erasca announced Wednesday that enrollment had [opened for testing](https://www.globenewswire.com/news-release/2026/11/04/3395309/0/en/tango-and-erasca-initiate-phase-1-2-study-of-oral-prmt5-inhibitor-vopimetostat-in-combination-with-pan-ras-molecular-glue-eras-0015.html?ref=bullished.co) vopimetostat with ERAS-0015\. The Tango-sponsored early- to mid-stage study covers MTAP-deleted pancreatic cancer and MTAP-deleted, RAS-mutant non-small cell lung cancer. Testing will establish the maximum tolerated dose before expanding.

A separate early- to mid-stage combination study, planned for the first half of 2027, will enroll approximately 25 pancreatic-cancer patients without an MTAP deletion. Tango wants to test its hypothesis that benefits from pairing vopimetostat with pan-RAS inhibitors could extend to those tumors.

Tango expects January 2027 data on vopimetostat used alone in lung cancer and on TNG456 in lung cancer, glioblastoma and other cancers, alongside its lung-cancer development strategy.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Tango Therapeutics, Inc. (TNGX)](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526452635/tngx-20260811.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tngx-ex99\_1.htm — Tango Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526452635/tngx-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5](https://www.globenewswire.com/news-release/2026/11/04/3395309/0/en/tango-and-erasca-initiate-phase-1-2-study-of-oral-prmt5-inhibitor-vopimetostat-in-combination-with-pan-ras-molecular-glue-eras-0015.html?ref=bullished.co) — globenewswire.com

### More on Tango Therapeutics

- [Tango's Pancreatic Cancer Combo Shows 82% Response Rate As It Cuts About 14% Of Its Workforce](https://www.bullished.co/tangos-pancreatic-cancer-combo-shows-82-response-rate-as-it-cuts-about-14-of-its-workforce-86f477c2/)

[All Tango Therapeutics (TNGX) coverage →](https://www.bullished.co/tag/tngx/)